Large-Vessel Giant Cell Arteritis following COVID-19-What Can HLA Typing Reveal?
Giant cell arteritis (GCA) is an immune-mediated vasculitis that affects large arteries. It has been hypothesized that viruses may trigger inflammation within the vessel walls. Genetic studies on human leukocyte antigens (HLAs) have previously reported HLA-DRB1*04 as a susceptible allele for GCA and HLA-DRB1*15 as a protective allele for GCA. Here, we discuss the clinical presentation, laboratory findings, HLA class I and class II analysis results, and management of patients with extracranial large-vessel (LV) GCA, detected at least six weeks after recovery from COVID-19. This case series encompassed three patients with LV-GCA (two males and a female with an age range of 63-69 years) whose leading clinical presentation included the presence of constitutional symptoms and significantly elevated inflammatory markers. The diagnosis of LV-GCA was confirmed by CT angiography and FDG-PET/CT, revealing inflammation in the large vessels. All were treated with corticosteroids, while two received adjunctive therapy. By analyzing HLA profiles, we found no presence of the susceptible HLA-DRB1*04 allele, while the HLA-DRB1*15 allele was detected in two patients. In conclusion, LV-GCA may be triggered by COVID-19. We highlight the importance of the early identification of LV-GCA following SARS-CoV-2 infection, which may be delayed due to the overlapping clinical features of GCA and COVID-19. The prompt initiation of therapy is necessary in order to avoid severe vascular complications. Future studies will better define the role of specific HLA alleles in patients who developed GCA following COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Diagnostics (Basel, Switzerland) - 13(2023), 3 vom: 28. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stojanovic, Maja [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmunity |
|---|
| Anmerkungen: |
Date Revised 28.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/diagnostics13030484 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35276306X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35276306X | ||
| 003 | DE-627 | ||
| 005 | 20231226054449.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/diagnostics13030484 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM35276306X | ||
| 035 | |a (NLM)36766589 | ||
| 035 | |a (PII)484 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stojanovic, Maja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Large-Vessel Giant Cell Arteritis following COVID-19-What Can HLA Typing Reveal? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Giant cell arteritis (GCA) is an immune-mediated vasculitis that affects large arteries. It has been hypothesized that viruses may trigger inflammation within the vessel walls. Genetic studies on human leukocyte antigens (HLAs) have previously reported HLA-DRB1*04 as a susceptible allele for GCA and HLA-DRB1*15 as a protective allele for GCA. Here, we discuss the clinical presentation, laboratory findings, HLA class I and class II analysis results, and management of patients with extracranial large-vessel (LV) GCA, detected at least six weeks after recovery from COVID-19. This case series encompassed three patients with LV-GCA (two males and a female with an age range of 63-69 years) whose leading clinical presentation included the presence of constitutional symptoms and significantly elevated inflammatory markers. The diagnosis of LV-GCA was confirmed by CT angiography and FDG-PET/CT, revealing inflammation in the large vessels. All were treated with corticosteroids, while two received adjunctive therapy. By analyzing HLA profiles, we found no presence of the susceptible HLA-DRB1*04 allele, while the HLA-DRB1*15 allele was detected in two patients. In conclusion, LV-GCA may be triggered by COVID-19. We highlight the importance of the early identification of LV-GCA following SARS-CoV-2 infection, which may be delayed due to the overlapping clinical features of GCA and COVID-19. The prompt initiation of therapy is necessary in order to avoid severe vascular complications. Future studies will better define the role of specific HLA alleles in patients who developed GCA following COVID-19 | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HLA | |
| 650 | 4 | |a SARS-CoV-2 infection | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a giant cell arteritis | |
| 650 | 4 | |a large-vessel vasculitis | |
| 700 | 1 | |a Barac, Aleksandra |e verfasserin |4 aut | |
| 700 | 1 | |a Petkovic, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Vojvodic, Nikola |e verfasserin |4 aut | |
| 700 | 1 | |a Odalovic, Strahinja |e verfasserin |4 aut | |
| 700 | 1 | |a Andric, Zorana |e verfasserin |4 aut | |
| 700 | 1 | |a Miskovic, Rada |e verfasserin |4 aut | |
| 700 | 1 | |a Jovanovic, Dragana |e verfasserin |4 aut | |
| 700 | 1 | |a Dimic-Janjic, Sanja |e verfasserin |4 aut | |
| 700 | 1 | |a Dragasevic, Sanja |e verfasserin |4 aut | |
| 700 | 1 | |a Raskovic, Sanvila |e verfasserin |4 aut | |
| 700 | 1 | |a Stjepanovic, Mihailo I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostics (Basel, Switzerland) |d 2011 |g 13(2023), 3 vom: 28. Jan. |w (DE-627)NLM250111136 |x 2075-4418 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:3 |g day:28 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/diagnostics13030484 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 3 |b 28 |c 01 | ||